Q3 Preview: A Stabilizing Quarter For J&J In China?
This article was originally published in PharmAsia News
Executive Summary
Since J&J reported in July a slowdown for its sales for China, the Chinese economy has deteriorated further. Can several new initiatives help the largest U.S. healthcare company to recover in this critical market?